Kornimate/medical-research-clean huggingface dataset:
conservative management of cutaneous abscess

Conditions: Cutaneous Abscess

Summary: this is a single center non-blinded randomized trial of topical anesthetic cream to usual care (warm compresses and time) for superficial, non-perianal abscesses in children under 18 years of age. the primary outcome is time to spontaneous drainage. the secondary outcomes are return to emergency room/hospital/care provider and need for incision and drainage. information on patient experience using standardized patient reported outcome measures for health-related quality of life will also be gathered. the findings of this study will provide more robust evidence of the benefit of this treatment including a potential reduction in cost and allow for more widespread dissemination.

cutaneous abscesses are a common problem in the pediatric population, leading to a substantial number of emergency room and primary care visits each year. historically, treatment consisted of antibiotics and surgical drainage, but as our understanding of these disease processes has progressed, treatment has moved away from invasive drainage procedures except when necessary. now, most patients are treated with warm compresses or warm baths to the area until spontaneous resolution occurs. recent data has demonstrated that the application of topical anesthetic cream to a cutaneous abscess underneath a non-permeable dressing can lead to improved rates of spontaneous drainage. although this method is being used with success at our institution, its true benefit is unknown, preventing widespread dissemination of the practice. we are therefore proposing a prospective trial to evaluate the benefit of this treatment on pediatric patients. this is a single center non-blinded randomized trial of topical anesthetic cream to usual care (warm compresses and time) for superficial, non-perianal abscesses in children under 18 years of age. the primary outcome is time to spontaneous drainage. the secondary outcomes are return to emergency room/hospital/care provider and need for incision and drainage. information on patient experience using standardized patient reported outcome measures for health-related quality of life will also be gathered. the findings of this study will provide more robust evidence of the benefit of this treatment including a potential reduction in cost and allow for more widespread dissemination.

Eligibility criteria:
inclusion criteria: * \<18 years of age * single, localized soft tissue abscess \<3 cm in size by clinical or imaging criteria exclusion criteria: * signs of systemic illness/infection including but not limited to temperature \> 100.4, lethargy, or poor oral intake; * a decision by an attending physician that incision and drainage is necessary; * inpatient admission; immunocompromised patients; soft tissue abscesses involving the perineum (labia, scrotum, penis, perianal), hands/feet, or face; * previous antibiotic use in the past seven days or previous attempt by a clinician/provider at drainage; * current drainage from abscess. * lidocaine allergy
combination chemotherapy in treating patients with stage i, ii, or iiia non-small cell lung cancer that has been surgically removed

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: randomized phase iii trial to compare cisplatin and etoposide with no chemotherapy in treating patients who have stage i, stage ii, or stage iiia non-small cell lung cancer that has been surgically removed.

objectives: * assess the efficacy of the combination of cisplatin and etoposide after radical surgery in prolonging the relapse free and overall survival for stages i, ii, and iiia non-small cell lung cancer. outline: this a randomized study (treatment vs no treatment). patients are stratified according to sex and to stage of disease (i vs ii vs iiia). patient receives cisplatin and etoposide on days 1-3, every 28 days, for 3 cycles. patient may receive radiation therapy after surgery at the discretion of the physician. projected accrual: approximately 750 patients will be accrued over 3 years.

Eligibility criteria:
disease characteristics: * histologically proven stage i, ii, or iiia non-small cell lung cancer after radical surgery * no evidence of lymphonodal enlargement during postsurgical chest ct scan patient characteristics: age: * 70 and under performance status: * ecog 0-2 life expectancy: * not specified hematopoietic: * wbc at least 3,500/mm3 * platelet count at least 100,000/mm3 hepatic: * not specified renal: * creatinine no greater than 1.5 times the upper limit of normal pulmonary: * fev1 at least 1 liter other: * less than 10% weight loss in the past 3 months * no prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * not specified surgery: * radical surgery required

Keywords: stage i non-small cell lung cancer stage ii non-small cell lung cancer stage iiia non-small cell lung cancer
use of non-ablative vaginal erbium yag laser for the treatment of stress urinary incontinence.

Conditions: Urinary Incontinence,Stress

Summary: this is a single center, investigator initiated study, sponsored by the uz leuven, leuven, belgium; comparing laser treatment to pelvic floor exercises (pfe). women with symptomatic stress urinary incontinence who seek for a conservative treatment, with no history of previous incontinence-surgery will be randomised to either the laser-arm or the pfe-arm. there are 3 visits (with a maximum of 6 visits) where vaginal application of laser will be performed, with a 4-weeks interval. each application lasts around 15 minutes. the vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators. the primary objective is to evaluate the effects of vel treatment for the subjective cure or improvement of sui. the secondary objectives are to measure objective outcomes, to register any adverse events, and to determine for how long the effects of laser are sustained, with a maximum of two years.


Eligibility criteria:
inclusion criteria: * the presence of mild (score 1-2) to moderate (3-6) sui with wish for treatment. the patient can have concomitant urge urinary incontinence (uui), but that should not be the leading factor. incontinence severity will be categorized by the four-level sandvik severity index score (sis). scores are from 0 to 12. the higher the score, the more severe the urinary incontinence (mild=1-2, moderate= 3-6, severe=8-9, very severe=12). * voluntary informed consent exclusion criteria: * any previous pfe-treatment in the last year for the same problem * previous surgery for incontinence or prolapse * severe (sandvik sis ≥8) sui or insensible loss, high suspicion of intrinsic sphincter deficiency (isd) * prolapse grade iii or more * pregnancy * vaginal bleeding, injuries or infection in the treated area
orient: olmesartan reducing incidence of end stage renal disease in diabetic nephropathy trial

Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus; Proteinuria

Summary: the purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of diabetic nephropathy in patients with type 2 diabetes * albumin-to-creatinine ratio \>= 300 mg/g creatinine in first morning urinalysis * serum creatinine between 1.0 and 2.5 mg/dl in women and between 1.2 and 2.5 mg/dl in men exclusion criteria: * type 1 diabetes * non-diabetic nephropathy * history of myocardial infarction * history of cardiac bypass grafting within 3 months * history of percutaneous coronary intervention (pci) within 6 months * history of carotid artery or peripheral artery revascularization within 6 months * stroke or transient ischemic attack (tia) within 1 year * unstable angina pectoris * heart failure of nyha functional classes iii or iv * rapid progression of kidney disease within 3 months * severe orthostatic hypotension * serum potassium level =\ 5.5 meq(mmol)l * history of rapid elevation of the serum creatinine level after starting treatment with aii receptor antagonists or ace inhibitors * poor glycemic control: hba1c level =\>11% * history of myocardial infarction (mi) or coronary artery bypass grafting (cabg) within 3 months

Keywords: angiotensin ii type i receptor blockers diabetic nephropathy end-stage renal disease renal failure type 2 diabetes olmesartan medoxomil
analysis of laboratory markers for severe covid-19

Conditions: Coronavirus Infection COVID-19

Summary: the course of coronavirus infection was often severe and required hospitalization of patients in the intensive care unit. the new sars-cov-2 has been poor studied, so relatively reliable markers are needed to effectively monitor patients and predict complications and outcome. taking into account the known mechanisms of pathogenesis, the biochemical markers as ferritin, procalcitonin, c-reactive protein and d-dimer were chosen for this purpose. patients were divided according to the degree of pulmonary infiltration. we hypothesized that the markers would correlate with dynamics, complications, and outcomes.

in the presented study, an analysis of the medical records of 193 patients hospitalized in severe condition to the intensive care unit with a confirmed diagnosis of coronavirus infection covid-19 was carried out. taking into account the volume of pulmonary infiltration according to computer tomography (ct) of the chest organs, patients were divided into 4 groups in accordance with the approved classification: ct 1(up to 25% of lung tissue was infiltrated) - 27 patients, ct 2 (25-50%) - 60 patients, ct 3 (50-75%) - 67 patients, ct 4 (75% and more) - 39 patients. the following biochemical parameters were selected and used to monitor dynamics: procalcitonin (pct), c-reactive protein (crp), d-dimer (dd), ferritin (frt). the duration of observation was 15 days. in order to determine correlations between quantitative and qualitative data at different stages of treatment, a correlation analysis was carried out (spearman's test was used). roc analysis was performed to evaluate selected laboratory markers as predictors of outcome. next, the odds ratio (or) was assessed taking into account the obtained youden's j index and the associated criterion for each of the selected markers in relation to the patient's outcome. preliminary contingency tables were compiled in relation to laboratory parameters and outcomes (2x2 tables). data were processed using statistical software jamovi (computer software ,version 2.3.26), medcalc (medcalc software ltd, ostend, belgium), microsoft office excel, 2016.

Eligibility criteria:
inclusion criteria: * identified covid-19 by nasopharyngeal material pcr, coronavirus associated lung infiltration, visualized by ct, and clinically severe condition exclusion criteria: * pregnancy

Keywords: coronavirus infection covid-19 biochemical markers forecasting outcomes resuscitation and intensive care
comparison of clinical outcomes between all-inside and complete tibial tunnel techniques in anterior cruciate ligament reconstruction among patients with acl ruptures

Conditions: Anterior Cruciate Ligament Rupture

Summary: this study aims to compare the functional outcomes of patients with acl rupture following acl reconstruction surgery using hamstring grafts, between the all-inside technique and the complete tibial tunnel technique. the hamstring graft, which serves as the tissue substitute for the damaged acl, is harvested from the posterior thigh of the patient and used to replace the torn ligament during reconstruction

this study was conducted usingdouble blind randomized controlled trial (rct), patients who agree to participate in the study will be randomized to undergo acl reconstruction using either the all-inside technique or the complete tibial tunnel technique. clinical outcomes, including tibial translation, pain severity, ikdc score, and tegner score, will be evaluated through anamnesis and physical examination at the outpatient orthopedic clinic at 3, 6, 9, and 12 months postoperatively.

Eligibility criteria:
inclusion criteria: * patients with anterior cruciate ligament rupture * patients within the age range of 18 to 65 years exclusion criteria: * patients with multiple ligament injuries in the knee joint * patients with a pregnancy condition * patients with severe osteochondral defect (icrs 4) * patients with signs of inflamation in knee joint

Keywords: all-inside techniques
impact of pharmacist-led cognitive behavioral intervention on adherence and quality of life of epileptic patients

Conditions: Epilepsy

Summary: the purpose of this interventional study is to assess the impact of pharmacist-led cognitive behavioral intervention in epileptic patients. the main questions are: 1. if pharmacist-led cognitive behavioral therapy can help in improving patient medication adherence? 2. how will the cognitive behavioral therapy impact the quality of life of the patients? participants of this study will be provided basic or advanced level counselling and educational material as part of their routine pharmacy visit. researchers will compare the two groups (basic and advanced) to see which of the two groups are better in term of medication adherence and quality of life.

the purpose of the study is to investigate whether incorporation of pharmacist-led cognitive behavioral therapy (cbt) to the treatment of epileptic patients can result in better adherence to anti epileptic drugs. in order to manage epilepsy effectively, medication adherence is essential. missed doses or irregular drug use can increase the frequency of seizures and reduce the effectiveness of treatment. in order to improve medicine adherence rates, the study will examine if cognitive behavioral therapy (cbt) therapies can have a favorable effect on patients' motivation, coping techniques, medication beliefs, reduction in adverse drug reaction (adrs), seizures frequency and medication related problems (mrps) other than adverse drug reaction (adrs) and overall quality of life of epileptic patients.

Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis. * patients treated for epilepsy with at least one anti epileptic drug, subjects willing to participate in the study with or without other severe co-morbidities were included in the study. exclusion criteria: * pregnant female patients. * patients who provide incomplete information * patients with any terminal disease e.g., end stage renal disease * patients not willing to participate were excluded from the study.

Keywords: cognitive behavioral therapy pharmacist medication adherence quality of life
swiss prospective cohort of transgender and gender diverse individuals - the spectra study

Conditions: Transgender Individuals; Gender Incongruence

Summary: the goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (tgd) individuals undergoing gender-affirming therapies in switzerland. the study population includes tgd individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned. the main question is: what are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies? researchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies. participants will: complete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes. provide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis. undergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.


Eligibility criteria:
inclusion criteria: * age 16 years and above. * established diagnosis of gender incongruence * indication for gender affirming therapy or ongoing or discontinued gender affirming therapy exclusion criteria: * unable to give informed consent * missing commitment or ability to study protocol adherence
plasma purification and chronic hepatitis b

Conditions: Chronic Hepatitis b

Summary: to compare the efficacy of nucleoside analogues （ha） alone and plasma purification +ha in reducing hbv viral load.

chronic hepatitis b (chb) is a major disease harmful to human health and an important cause of liver cirrhosis and liver cancer. hepatitis b virus (hbv) cccdna exists for a long time in the liver of infected persons and serves as a template for hbv replication, which makes it difficult to eradicate hepatitis b virus infection. antiviral drugs are commonly used clinically, including interferon and nucleoside analogues, but there are problems of recurrence and drug resistance. these drugs are not directly targeted at cccdna and are therefore inefficient at reducing cccdna. how to quickly and efficiently reduce the viral load of hbv-dna, inhibit the transcription of hbv-cccdna rna, and promote the negative conversion of hbeag is an urgent problem to be solved at present, so it is particularly important to find other more effective drugs or methods. plasma purification is a new treatment method in which the pathogenic factors (hepatitis b virus, etc.) are trapped in the hollow fibers by special membrane materials and removed. therefore, this study adopts the randomized control method to explore the effect of plasma purification on hbv clearance, aiming to explore the effectiveness and safety of plasma purification in reducing hbv dna viral load and inhibiting hbv cccdna rna transcription, so as to provide new treatment ideas and methods for future treatment of hepatitis b virus infection, which is beneficial to the society and individuals.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of chronic hepatitis b disease 2. hepatitis b virus hbeag is positive 3. hepatitis b virus hbv-dna virus load is more than 100000cps/ml exclusion criteria: 1. hypotension 2. cardiopulmonary insufficiency 3. coagulation disorders 4. heparin allergy
a multisensory music intervention for children with reading disorders (ritmoz)

Conditions: Reading Disorder

Summary: with this study, we wish to test how effective/ beneficial music activities can be for children with dyslexia.

studies have shown that music in the form of training (i.e., intervention) is able to facilitate linguistic processes (e.g., phonological encoding/decoding, categorical perception) and cognitive functions (e.g., working memory) in children that have dyslexia or reading difficulties. in addition to this, music trainings with a focus on entrainment can improve phonological as well as reading skills. in line with the above, we have designed and developed a music training programme. this programme, which is called ritmoz training (i.e., from ritmus és mozgás és zene: meaning rhythm and movement and music in hungarian language), is designed for (hungarian) children who have dyslexia or reading difficulties. in order to assess the efficacy of the music training, we are going to conduct a randomized controlled trial which consists of a pre-training phase, a training phase and a post-training phase.

Eligibility criteria:
inclusion criteria: * diagnosis of reading disorder * hungarian as native language exclusion criteria: * comorbidities (e.g., attention deficit disorder (add), attention deficit hyperactivity disorder (adhd)) * sensory impairment (e.g., hearing loss, low vision) * cognitive impairment (e.g., panic disorder, low iq)

Keywords: reading disorders music intervention rhythmic stimulations phonological processing event-related brain potentials
intravitreal bevacizumab combined with pdt versus bevacizumab to treat exudative amd

Conditions: Macular Degeneration

Summary: the purpose of this study is to determine the association of bevacizumab and pdt is safety and effective in the treatment of exudative amd

exudative amd is the leader of blind in people more than 60 years. the best treatment for this disease today are monthly injections of anti-vegf in the vitreous cavity which increase the chance to get endophthalmites. the participants of this study will be randomized in 1:1 ration to one of the two study groups: single therapy of bevacizumab (3 injections in 3 months) or association of bevacizumab (3 injections in 3 months) and full fluence of pdt (single at the baseline). all bevacizumab injection will contain 1.25g of the drug and will be administrate every month for 3 continuos months. after randomization, participants will return to the clinic approximately every four weeks for 4 months for study assessments and possible re-treatment (if is necessary). participants will return to the clinic at week 20 for a final study assessment. study assessments include: visual acuity, optical coherence tomography and fundus photography.

Eligibility criteria:
inclusion criteria: * more or iqual 50 years old * male or female * choroidal neovascularization sub or just foveal the fovea secondary to amd (predominantly classic, minimally classic, and occult lesions acceptable) * greatest linear dimension (gld) of entire lesion \< 5400 µm (no reading center confirmation required) * etdrs best corrected visual acuity of 20/40 - 20/320 (73 - 24 letter score) * total area of lesion must \< 9 mps da exclusion criteria: * pre-treatment * etdrs best corrected visual acuity better than 34 letters * macular surgery history * laser photocoagulation in the study eye within 30 dais * eye surgery within 30 days * history of no-treat glaucoma * acuite uveits * history of endophthalmites * vitreous hemorrhage * geographic atrophy or fibrosis corresponding \> 50% of the lesion

Keywords: amd pdt avastin bevacizumab full fluence exudative cnv drusen armd vetaporfin efficacy treatment
post-authorization safety study of gsk biologicals' pandemic influenza vaccine (h1n1) in the united kingdom

Conditions: Influenza

Summary: the focus of this study is to assess the safety of gsk's h1n1 vaccine in real life conditions as soon as the vaccine is used, in a mass vaccination programme, and with a system for rapid generation, communication and evaluation of safety data. this study is a commitment to the european medicines agency (emea), as part of glaxosmithkline biologicals' (gsk biologicals') risk management plan for pandemic influenza vaccination.

collaborator: medicines and healthcare products regulatory agency

Eligibility criteria:
inclusion criteria: * written informed consent, and assent where appropriate, obtained from the subject/from the subject's parent(s)/ legally acceptable representative(s) (lar). * a male or female subject vaccinated with a first dose of gsk biologicals' h1n1 pandemic influenza vaccine * shortly (\<24h) before being recruited in the study, and * within a gp practice participating in the study and where the subject is registered. * subjects who the investigator believes that they and/or their parent(s)/lar can and will comply with the requirements of the protocol exclusion criteria: * subjects already vaccinated with any other h1n1 pandemic vaccine before study enrolment. * child in care

Keywords: safety influenza vaccine reactogenicity swine flu